产品
编 号：F117432
分子式：C18H18ClNO4S
分子量：379.86
分子式：C18H18ClNO4S
分子量：379.86
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1314081-53-2
产品详情
生物活性：
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
体内研究：
Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats.Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose.Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse.Animal Model:Male Wistar rats(200?250 g)
Dosage:3 mg/kg
Administration:oral
Result:Inhibitied platelet aggregation by ADP-induced in rats.
Animal Model:SD male rats
Dosage:1.14 mg/mL
Administration:oral, 0-24 h
Result:Could be readily converted into clopidogrel thiolactone and had high bioavailability.
Animal Model:Mice
Dosage:5 g/kg
Administration:oral, single, for 14 days
Result:Had very low acute toxicity.
体外研究：
Vicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal.
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
体内研究：
Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats.Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose.Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse.Animal Model:Male Wistar rats(200?250 g)
Dosage:3 mg/kg
Administration:oral
Result:Inhibitied platelet aggregation by ADP-induced in rats.
Animal Model:SD male rats
Dosage:1.14 mg/mL
Administration:oral, 0-24 h
Result:Could be readily converted into clopidogrel thiolactone and had high bioavailability.
Animal Model:Mice
Dosage:5 g/kg
Administration:oral, single, for 14 days
Result:Had very low acute toxicity.
体外研究：
Vicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备